In this study, we aimed to explore the functional relevance of ZIP7 and ZIP6/10 heteromers to TAMR breast cancer cells in comparison to non-resistant models of disease, in an attempt to validate anti-ZIP agents as a novel therapeutic target for resistant disease. Here, SLC39A7 is linked to breast carcinoma.